Antidepressant use during pregnancy: The benefit-risk ratio

Keyphrases

• During Pregnancy 100%
• Antidepressant Use 100%
• Risk-benefit Ratio 100%
• Selective Serotonin Reuptake Inhibitors 66%
• Serotonin-norepinephrine Reuptake Inhibitors 66%
• Fetus 33%
• Fetal Exposure 33%
• Newborn Infant 33%
• Pregnant Women 33%
• Psychiatric Conditions 33%
• Evidence-based 33%
• Antidepressants 33%
• Fetal Risk 33%
• Maternal Exposure 33%
• Healthcare 33%
• Cardiac Malformation 33%
• Potential Risk 33%
• Pharmacotherapy 33%
• Persistent Pulmonary Hypertension of the Newborn 33%
• Poor Neonatal Adaptation Syndrome 33%
• Maternal Well-being 33%
• Primary Pulmonary Hypertension 33%
• Minimal Risk 33%

Medicine and Dentistry

• Risk-Benefit Ratio 100%
• Antidepressant 100%
• Selective Serotonin Reuptake Inhibitor 66%
• Drug Therapy 33%
• Congenital Malformation 33%
• Health Care 33%
• Fetus Risk 33%
• Maternal Exposure 33%
• Norepinephrine Reuptake Inhibitor 33%
• Pulmonary Hypertension 33%
• Mental Disorder 33%
• Serotonin-Norepinephrine Reuptake Inhibitor 33%
• Adaptation Syndrome 33%
• Pregnant Woman 33%
• Newborn Infant 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Antidepressant 100%
• Selective Serotonin Reuptake Inhibitor 100%
• Congenital Malformation 50%
• Syndrome 50%
• Pharmacotherapy 50%
• Fetus Risk 50%
• Maternal Exposure 50%
• Norepinephrine Reuptake Inhibitor 50%
• Serotonin-Norepinephrine Reuptake Inhibitor 50%
• Pulmonary Hypertension 50%